Press releaseGlobe Newswire
Annovis Bio
ANVS · NYSE
$0.9783+$0.0183 (+1.91%)TodayMarket closed ·
Prev close $0.96
Latest news
- Press releaseGlobe Newswire
Annovis to Host Corporate Update Webinar on September 2, 2026
- Press releaseGlobe Newswire
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
- News
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028
- Press releaseGlobe Newswire
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
- Press releaseGlobe Newswire
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
- Press releaseGlobe Newswire
Annovis Bio Regains NYSE Listing Compliance
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why 8x8 Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
- Press releaseGlobe Newswire
The Credibility Filter Wall Street Uses to Sort Biotech Winners
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
- Press releaseGlobe Newswire
Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment
- NewsAvi Kapoor
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Annovis to Host Webinar and Live Q&A on June 24, 2025
- News
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseGlobe Newswire
Annovis to Host Patients' Live Forum on February 27, 2025
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
- Press releaseGlobe Newswire
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Disease Study, Streamlining Development Pathway
- Press releaseGlobe Newswire
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
- Press releasePRNewswire
/C O R R E C T I O N -- Today's Marketplace/
- Press releaseGlobe Newswire
Annovis to Host Year-End Investor Webcast on December 11, 2024
- Press releaseGlobe Newswire
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
- Press releaseGlobe Newswire
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
- Press releaseGlobe Newswire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
- Press releaseGlobe Newswire
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
- Press releaseGlobe Newswire
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs
- Press releasePRNewswire
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
- Press releaseGlobe Newswire
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
- Press releaseGlobe Newswire
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
- Press releasePRNewswire
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition
- Press releaseGlobe Newswire
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
- Press releaseGlobe Newswire
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
- Press releaseGlobe Newswire
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
- Press releaseGlobe Newswire
IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024
- NewsAvi Kapoor
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.